Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the initial-line procedure of CML-CP. Five hundred and nineteen sufferers with recently diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of one hundred mg after each day (259 patients) or imatinib https://elagabalusf186vjp3.wonderkingwiki.com/user